semaglutide manufacturing process novo nordisk synthesis EP3398960B1 Synthesis method of semaglutide -

Gether IM, Nexoe-Larsen C, Knop FK

Common transition side effects When switching from tirzepatide to semaglutide, some side effects may reappear, especially during the start of medication or during dose escalation

Apart from WEGOVY, SAXENDA , another Novo Nordisk weight loss drug, is also approved in the US for obesity

However, nausea is a common side effect of GLP-1 therapy itself, especially during the first 48 weeks of treatment, so layering a cold illness on top of existing GLP-1 nausea can compound digestive discomfort and dehydration risk

Our prior authorization support ensures you're spared the hassle, as we navigate through submission and follow-ups until approval